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 
Abstract— There is an unmet medical need for a more 
reliable and earlier assessment of patients suspected of having a 
deep vein thrombosis.  
Deep vein thrombosis (DVT) is an internal clot formed in one 
of the body's deep veins, usually one of those in the leg.  If a 
part of the clot breaks free and moves into the lung, it can lead 
to pulmonary embolism (PE), an often-fatal condition. It is 
essential that diagnosis is made quickly and accurately and that 
treatment is started promptly. 
Currently, patients cannot be fully assessed within primary 
care; they are referred for assessment to a secondary care 
setting, such as a clinic or hospital, using a combination of 
laboratory based blood test and expert clinical assessment. This 
causes potentially life-threatening delays to diagnosis and 
commencement of treatment for patients who do have a blood 
clot, it also causes unnecessary delays for patients who do not.  
During 2005 the number of reported incident cases of DVT 
and PE totalled 1.3 million in France, Spain, Germany, Italy, 
United Kingdom, Japan and United States alone. This figure is 
expected to rise to 1.4 million per annum by 2011, due to 
increase in population. Within these countries it is estimated 
that healthcare systems invest up to €6.6 billion annually in 
assessment of patients suspected to be suffering from 
thromboembolitic event, whose diagnosis proves to be negative. 
 
DVT-IMP, a Framework Programme 6 project, is innovating 
a highly reliable, accurate, portable and handheld prototype 
medical diagnostic device to improve radically the speed, 
accuracy and reliability with which DVT and related blood 
clotting conditions can be assessed.The device will measure 
whole blood concentration of D-dimer, a recognized biomarker 
of increased blood clotting activity, and through innovation in 
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the development of a novel detection, measurement and 
reporting system, will offer the opportunity to use the test in the 
point of care setting.  
 
D-dimer testing, in conjunction with clinical assessment, is 
already an integral part of the diagnosis of the presence of a 
blood clot. However since most quantitative currently available 
D-dimer tests are performed in the laboratory, these can 
generally only be offered in a hospital clinic. An analysis of 
current medical diagnostic practice and available tests indicates 
that practitioners in primary care, such as GP surgeries and 
community clinics would welcome access to a reliable point of 
care D-dimer test as it would improve the quality of care that 
they can provide to their patients, improve DVT healthcare 
diagnosis and treatment services, and hence improve patient 
outcomes. 
 
The device combines innovation in antibody bio-engineering 
for high specificity immunoassay-based diagnostics and 
nano/micro engineered impedimetric analysis electrodes 
incorporating biocompatible conducting polymer substrate with 
development of a disposable microfluidic manifold specifically 
enabling diagnostics at the point-of-first-contact and 
development of an advanced e-Health medical diagnostic 
software system. 
 
I. INTRODUCTION 
EVELOPMENT of an innovative medical diagnostic 
device to measure whole blood d-dimer concentration at 
point of care is described. It comprises a novel 
immunochemical biosensor and detection system within a 
disposable cartridge and with a reader for data management 
and transfer. 
The development of a thin film biosensor, comprising an 
antibody captured onto the surface of a printed electrode and 
capable of measuring concentration of a biomarker in whole 
blood, is described and the development of impedimetric 
detection, with appropriate blood handling, for measurement 
of biomarkers in whole blood is discussed. Concentration of 
d-dimer antigen in a sample of whole blood is measured by a 
novel impedimetric measurement system. The biosensor and 
detection system lie within a disposable cartridge, containing 
innovative whole blood handling capabilities and test and 
data management and transfer system are held within a base 
unit. 
 
Finally, the development of a disposable liquid handling 
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cartridge, with microfluidic system designed to manipulate a 
whole blood sample and capable of delivering the sample, in 
appropriate form, into the impedimetric measurement 
system, is described. 
 
II. DETECTION OF A BIOMARKER IN WHOLE BLOOD USING A 
THIN FILM BIOSENSOR WITH IMPEDIMETRIC DETECTION 
Whole blood D-dimer concentration is measured through 
detection of change in impedance at the measurement 
electrode as a result of binding of D-dimer molecules to the 
antibodies immobilized onto the electrode surface.  
A. Development of the Biosensor 
Biosensors increasingly use thin films incorporating active 
organic molecules. These layers either interface with, or act 
as, the transduction element of the sensor. The 
immobilisation of the active molecules can take a number of 
forms; for example, as monolayers directly attached to the 
sensor, as components in thin polymer films, or immobilised 
on supports, such as nanoparticles. In electrochemical 
biosensors, the active layer is interfaced with electrodes 
which react to changes in the electronic structure of the 
active layer, and which are detected by the measurement 
electronics. These changes, which are produced by chemical 
interactions between the molecules in the active layer and the 
analyte of interest, can be detected using a number of 
measurement techniques [1]. 
 
Commonly, microelectrodes produced from suitable 
conducting materials, such as gold, platinum, and silver are 
used as the interface electrodes. However, the development 
of techniques such as nanoimprint lithography (NIL) [2], 
focused ion beam (FIB) milling [3] and laser ablation, 
complemented by high-resolution etching techniques such as 
reactive ion etching (RIE) [4], have lead to the production of 
nanoelectrodes [5]. These nanoelectrode geometries 
potentially have advantages with respect to their micro-
fabricated analogues because they have improved spatial 
resolution and reduced signal noise [6]. 
 
Interfacing of the active layer molecules to nanoelectrodes 
is not a trivial subject, although there are a number of 
techniques that can be used. For example, if the molecules 
can be incorporated into a monomer precursor, they can be 
immobilised onto the electrodes using electropolymerisation 
[7]. In this case, the polymer itself may need to be 
conducting to facilitate electron transfer to the electrode 
surface [8]. Common electrically conducting polymers used 
in sensing applications include poly(pyrrole) [9] and 
poly(aniline) [10] and their derivatives. The active 
(bio)molecules can be covalently bonded to the polymers, 
using suitable coupling reactions, which may involve the use 
of reactive moieties, such as amine, acid or thiol groups, or 
simply immobilised in the polymer matrix. Positional control 
of the active layer using this technique is facile, as the 
polymer grows predominantly on the electrode surface. 
However, the addition of the supporting polymer in the 
sensing system introduces a level of complexity when 
modelling the sensors and when attempting to produce a 
number of sensors with high reproducibility. 
 
Direct immobilisation of the active (bio)molecules to the 
surface of an electrode can be completed using covalent 
bonding. One of the most commonly used techniques for this 
is the interaction between a thiol group and a gold electrode. 
For example, this technique has been extensively used for the 
immobilisation of (bio)molecules through self assembly [11]. 
Such self-assembly can be used to immobilise biological 
material [12] and can be positionally controlled using a soft 
lithography method, called micro-contact printing [13], 
down to nanometric scales [14]. The formation of a thiol 
linkage between the gold and the thiolated (bio)molecule 
means that the active molecule is directly linked to the 
electrode. Non-specific immobilisation either side of the 
electrodes should be avoided as long as the thiol group has 
no affinity for the underlying substrate. The same molecules 
can be deposited using dip-pen lithography [15]. 
 
The DVT-IMP project will attempt to produce 
nanoelectrodes on polymeric substrates onto which active 
(bio)molecules will be immobilised using 
electropolymerisation, micro-contact printing or dip-pen 
lithography techniques. These functionalised electrodes will 
be incorporated into the analysis system for the detection of 
D-dimer in whole blood at levels of < 300 ng/ml. We will 
concentrate on using impedimetric analysis techniques, due 
to the possibility of extracting data by measuring impedance 
across a number of frequencies, i.e. impedance spectroscopy 
[16]. 
B. Electrochemical Impedance Spectroscopy (EIS) label-
free detection 
To achieve a sensitivity of 1ng/ml in a range of 0-
3000ng/ml of D-dimer in whole blood there is a need to 
measure impedance change on the electrode with high 
precision.  
Electrochemical Impedance Spectroscopy (EIS) is a 
rapidly developing electrochemical technique for the 
characterization of biomaterial-functionalized electrodes and 
especially for the transduction of biosensing events at the 
electrodes. A proven series of experimental observations 
were done that antibody (or DNA strend) loaded 
electroconductive matrices (particularly polypyrrole) give 
concentration dependant responses when interrogated with 
EIS [17,18], this type of electroconductive matrix presents a 
high surface concentration of grafted biomolecules and the 
change of conformation brought by the biological 
recognition induces a change of the polymer conjugation, 
then inducing an amplification effect of the electrical 
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phenomenon. Moreover, a particular enhancement of the 
sensitivity of detection was observed in presence of redox 
probe [19]. The EIS, in adequate experimental conditions, 
represents a label-free technique for immunodetection. 
 
During this project chemical engineering is performed in 
order to optimize the control the orientation of the reduced 
antibody scFV fragments in the electroconductive matrix and 
the control of the electronic exchange by inclusion a specific 
redox species in the polymer structure in order to enhance 
the sensitivity of detection. A specific group will be grafted 
on some monomer of pyrrole in order to limit non specific 
adsorption on the functionalised electrode surface. Moreover 
the nanostructuration of the electrode and the nanoscale 
control of the biofunctionalisation will allow to reinforce 
integration of the detection function in the cartridge. 
 
III. DEVELOPMENT OF A NOVEL MICROFLUIDIC SYSTEM, 
DEVICE AND READER 
A. The Disposable Cartridge and liquid handling system 
The cartridge is designed to ensure robustness of sample 
and reagent transfer. Therefore, focus is put onto fluidic 
transfer properties rather than additional functionality. The 
nano- and microelectrodes for the impedimetric 
measurement will be housed in a sample chamber that can be 
accessed from both sample and reagent reservoirs. 
 
The cartridge will be fabricated using established 
technologies in polymer microfabrication. These include hot 
embossing to define the microfluidic channels and chambers, 
photolithography and nanoimprint lithography to structure 
the impedimetric electrodes and laser ablation for the 
passivation layer. Future scalability and the choice of mass 
manufacturing-friendly technologies are already at the center 
of consideration during this process design stage. 
 
Immobilisation of the D-dimer antibody onto the electrode 
will be performed in an open cartridge configuration. This 
will facilitate the immobilisation process and allow easy 
quality control of the biological receptor layers. However, it 
puts very high demand on the joining of the cartridge parts. 
To achieve this, recourse will be taken to existing and novel 
joining processes that minimize temperature, UV and solvent 
load to the biological receptor molecules while guaranteeing 
robust functionality of the cartridge. 
B. Reader Design and Functionality 
The device as a whole has been conceptualized and 
designed to be user friendly, and able to be operated by non-
expert users, such as practitioners, paramedics and ultimately 
by patients.  
It is designed as a microcontroller driven device, part of a 
complex system consisting of four component parts that, 
when combined, give rise to a device capable of measuring 
biomarker concentration under Point-of-Care conditions. 
During the measurement phase „cartridge‟ and „reader‟ 
will operate as one compound system to provide all required 
functionalities.  
In order to drive the blood sample from point of entry to 
the electrode and then to remove the unwanted blood sample 
components (plasma, red blood cells, other proteins, etc.) 
from the measurement site there must be a fluidic 
interconnection between cartridge and reader. For this 
purpose a micro-pump is situated in the reader that will move 
buffer solution and blood sample through the cartridge. 
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